Cardiol Therapeutics (CRDL) Return on Equity (2021 - 2026)

Cardiol Therapeutics has reported Return on Equity for 6 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity changed 0.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), and the FY2025 full-year result was 0.02%, changed 0.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, up from 0.02% in the prior quarter.
• The five-year high for Return on Equity was 0.01% in Q1 2022, with the low at 0.02% in Q3 2025.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.01% in 2024.
• Annual changes were most pronounced in 2022 — Return on Equity changed 0 bps — and 2024, when it fell 2 bps.
• Cardiol Therapeutics' Return on Equity stood at 0.01% in 2022, then climbed by 9 bps to 0.01% in 2023, then sank by 154 bps to 0.02% in 2024, then retreated by 7 bps to 0.02% in 2025, then surged by 31 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.02% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.